Your browser is no longer supported. Please, upgrade your browser.
Settings
PTCT PTC Therapeutics, Inc. daily Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.87 Insider Own0.50% Shs Outstand62.39M Perf Week1.29%
Market Cap3.15B Forward P/E- EPS next Y-2.30 Insider Trans-54.15% Shs Float60.82M Perf Month6.15%
Income-292.20M PEG- EPS next Q-1.29 Inst Own99.32% Short Float7.34% Perf Quarter-1.77%
Sales321.70M P/S9.80 EPS this Y-55.40% Inst Trans5.36% Short Ratio5.33 Perf Half Y8.50%
Book/sh8.47 P/B6.02 EPS next Y56.50% ROA-19.10% Target Price59.20 Perf Year27.53%
Cash/sh9.63 P/C5.29 EPS next 5Y-9.51% ROE-51.40% 52W Range30.79 - 59.89 Perf YTD6.08%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-13.65% Beta1.45
Dividend %- Quick Ratio3.10 Sales past 5Y64.80% Gross Margin95.70% 52W Low67.95% ATR2.46
Employees754 Current Ratio3.20 Sales Q/Q27.40% Oper. Margin-82.40% RSI (14)59.91 Volatility4.00% 5.10%
OptionableYes Debt/Eq0.60 EPS Q/Q-39.90% Profit Margin-90.80% Rel Volume1.15 Prev Close50.95
ShortableYes LT Debt/Eq0.56 EarningsApr 30 AMC Payout- Avg Volume837.73K Price51.72
Recom2.00 SMA206.32% SMA508.86% SMA20012.14% Volume69,038 Change1.50%
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Mar-16-17Reiterated RBC Capital Mkts Sector Perform $13 → $10
Mar-03-17Downgrade Barclays Overweight → Equal Weight $20 → $13
Jun-01-20 08:00AM  
May-28-20 09:00AM  
May-27-20 07:04PM  
May-26-20 08:00AM  
May-21-20 04:27PM  
01:10AM  
May-15-20 04:30PM  
May-06-20 04:30PM  
May-05-20 08:00AM  
Apr-30-20 06:35PM  
Apr-28-20 01:00AM  
Apr-23-20 12:32PM  
Apr-22-20 04:30PM  
Apr-17-20 08:00AM  
Apr-16-20 08:00AM  
Apr-09-20 10:16AM  
Apr-07-20 04:05PM  
Mar-30-20 06:06PM  
Mar-29-20 12:32PM  
Mar-25-20 09:04AM  
Mar-16-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 11:53AM  
Mar-04-20 09:40AM  
Mar-02-20 05:25PM  
04:01PM  
Feb-25-20 04:30PM  
Feb-24-20 12:30PM  
Feb-18-20 08:00AM  
Feb-17-20 04:30PM  
Feb-06-20 04:08PM  
10:41AM  
05:00AM  
Feb-03-20 04:30PM  
08:05AM  
08:00AM  
Jan-23-20 08:51AM  
01:00AM  
Jan-13-20 08:00AM  
Jan-07-20 12:09PM  
Jan-06-20 08:00AM  
Dec-26-19 11:58AM  
Dec-19-19 10:09AM  
Dec-13-19 04:30PM  
Dec-04-19 10:23PM  
Dec-03-19 10:09AM  
Nov-29-19 04:30PM  
Nov-25-19 04:59PM  
Nov-21-19 11:22AM  
Nov-19-19 08:00AM  
Nov-18-19 08:00AM  
Nov-12-19 09:43AM  
Nov-11-19 01:00AM  
Nov-04-19 11:42PM  
Oct-31-19 04:30PM  
Oct-29-19 06:55PM  
04:01PM  
Oct-24-19 12:26PM  
08:00AM  
Oct-23-19 06:45PM  
04:30PM  
Oct-15-19 08:31AM  
Oct-07-19 08:00AM  
Oct-04-19 08:00AM  
Oct-02-19 08:00AM  
Sep-27-19 08:00AM  
Sep-20-19 04:30PM  
Sep-18-19 11:34AM  
08:25AM  
08:24AM  
Sep-17-19 04:01PM  
04:01PM  
Sep-11-19 03:03PM  
Sep-06-19 08:00AM  
Aug-19-19 10:51AM  
Aug-07-19 02:24AM  
Aug-06-19 06:25PM  
04:01PM  
Aug-05-19 08:00AM  
Jul-31-19 04:30PM  
Jul-30-19 10:38AM  
Jul-23-19 08:00AM  
Jul-19-19 08:09AM  
Jul-10-19 05:41PM  
Jul-01-19 09:21AM  
08:00AM  
Jun-28-19 06:40AM  
Jun-14-19 01:49PM  
Jun-13-19 09:44AM  
Jun-07-19 03:02PM  
01:31PM  
Jun-03-19 08:00AM  
May-31-19 04:30PM  
May-30-19 08:00AM  
May-20-19 08:00AM  
May-09-19 04:05PM  
May-08-19 04:12PM  
08:00AM  
May-07-19 04:33PM  
01:00AM  
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peltz Stuart WalterChief Executive OfficerMay 20Option Exercise10.8533,788366,60089,873May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 20Sale50.0033,7881,689,40056,085May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 18Option Exercise10.856,28468,18162,369May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 18Sale50.126,284314,97956,085May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 05Option Exercise10.85109,9281,192,719166,013May 07 03:44 PM
Peltz Stuart WalterChief Executive OfficerMay 05Sale50.34109,9285,533,59256,085May 07 03:44 PM
Jacobson Allan StevenDirectorApr 20Option Exercise10.8517,900194,21526,398Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 20Sale51.0417,900913,5588,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Option Exercise18.012,14538,63111,449Apr 21 04:15 PM
Jacobson Allan StevenDirectorApr 17Option Exercise10.852,10022,78510,598Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 17Sale50.162,100105,3328,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Sale50.002,145107,2509,304Apr 21 04:15 PM
Utter Christine MarieSVP, Finance & CAOApr 03Option Exercise11.237878,83810,091Apr 07 04:05 PM
Utter Christine MarieSVP, Finance & CAOApr 03Sale44.3178734,8729,304Apr 07 04:05 PM
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
Souza MarcioChief Operating OfficerFeb 10Option Exercise12.926258,0757,369Feb 12 04:09 PM
Souza MarcioChief Operating OfficerFeb 10Sale53.9262533,7006,744Feb 12 04:09 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Option Exercise10.8550,000542,50073,987Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.004,040222,2001,912Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.0050,0002,750,00027,089Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 05Sale55.0040522,2755,952Feb 07 04:41 PM
Hill Emily LuisaChief Financial OfficerJan 23Sale53.2533017,5726,891Jan 27 04:14 PM
Peltz Stuart WalterChief Executive OfficerJan 23Sale53.2542322,52318,102Jan 27 04:12 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 23Sale53.25462,4495,987Jan 27 04:09 PM
Souza MarcioChief Operating OfficerJan 23Sale53.251548,2005,074Jan 27 04:15 PM
Utter Christine MarieSVP, Finance & CAOJan 07Option Exercise15.7813,750216,95012,724Jan 08 06:07 PM
Hill Emily LuisaChief Financial OfficerJan 07Sale49.62633,1267,221Jan 08 06:03 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale49.62592,9286,033Jan 08 06:06 PM
Utter Christine MarieSVP, Finance & CAOJan 07Sale50.0213,750687,7335,224Jan 08 06:07 PM
Souza MarcioChief Operating OfficerJan 06Sale48.17864,1425,228Jan 08 06:09 PM
Utter Christine MarieSVP, Finance & CAOJan 06Sale48.1736017,3405,224Jan 08 06:07 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.171276,1176,092Jan 08 06:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.1750724,42116,889Jan 08 06:06 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.1779838,43818,525Jan 08 06:04 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.171,79786,55823,085Jan 08 06:04 PM
Hill Emily LuisaChief Financial OfficerJan 06Sale48.1732115,4627,284Jan 08 06:03 PM
Utter Christine MarieSVP, Finance & CAOJan 03Option Exercise11.237888,8496,372Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 03Sale47.4278837,3675,584Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Option Exercise11.232,36226,5257,946Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Sale47.892,362113,1115,584Jan 06 04:52 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise12.926,25080,75011,288Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise14.4275,8811,094,54468,221Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.806,250305,0005,038Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.9096,6954,728,73238,221Dec 26 05:24 PM
Peltz Stuart WalterChief Executive OfficerDec 03Option Exercise13.9718,981265,16926,332Dec 05 04:50 PM
Peltz Stuart WalterChief Executive OfficerDec 03Sale50.0022,4631,123,15018,676Dec 05 04:50 PM
Boulding Mark ElliottExec. VP and CLOJul 05Option Exercise15.1015,312231,27933,899Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 05Sale44.7415,312685,09729,524Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 01Option Exercise24.23104,0922,521,639100,373Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJul 01Option Exercise20.8113,071271,96814,234Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJul 01Sale45.1513,071590,1434,937Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJul 01Sale45.00104,0924,684,14029,524Jul 02 06:46 PM
Boulding Mark ElliottExec. VP and CLOJun 28Option Exercise11.3577,575880,72373,614Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJun 28Option Exercise20.8198820,5575,640Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJun 28Sale45.0098844,4604,937Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJun 28Sale45.0077,5753,490,87529,524Jul 02 06:46 PM